Seres Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 1.95 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 19.59M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Details
| Name | Seres Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 66 |
| Founded | 2010 |
| Ipo Date | 2015-06-26 |
| Ceo | Richard Kender |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US81750R2013 |
| Cusip | 81750R201 |
| Cik | 0001609809 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Richard N. Kender B.S., M.B.A. | Interim Chief Executive Officer and Executive Chair |
| Dr. Matthew R. Henn Ph.D. | President and Chief Scientific Officer |
| Thomas J. DesRosier Esq., J.D. | Executive Vice President, Chief Legal Officer and Secretary |
| Kelly Brady M.S. | Executive Vice President and Chief Operating Officer |
| Chris McChalicher | Executive Vice President and Chief Technology Officer |
| Dr. Dennis M. Walling M.D. | Senior Vice President of Clinical Development and Head of Clinical Research |
| Ann Kurowski | Senior Vice President of Regulatory Affairs |
Contact
| Address | 101 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States |
| Phone | 617 945 9626 |
| Website | https://www.serestherapeutics.com |